Kevin Chu Overview
- Firm
- F-Prime Capital
- Primary Position
-
Principal
- Primary Industry
-
Healthcare
- Active Board Seats
-
2
- Med. Deal Size
-
- Med. Valuation
-
Kevin Chu General Information
Biography
Mr. Kevin Chu serves as Principal at F-Prime Capital. He also serves as a Board Member at Amber Therapeutics and Arion Cancer Hospital. Prior to F-Prime Capital, He was an Associate Consultant with IMS Consulting Group in New York, where he advised biopharmaceutical clients on the development and commercial strategy across multiple therapeutic areas. He currently works closely with the Fidelity Growth Partners Asia team to manage portfolio companies and new investment opportunities in China. He received his B.S.E. in Biomedical Engineering from the University of Pennsylvania.
Contact Information
Address
- 140 New Montgomery Street
- 2nd Floor, Suite A
- San Francisco, CA 94105
- United States
Kevin Chu Positions (1)
| Firm name | Firm type | Title | Location | Industry | Since |
|---|---|---|---|---|---|
| F-Prime Capital | Investor | Principal | Cambridge, MA | Venture Capital |
Kevin Chu Board Seats (2)
| Company | Industry | Ownership Status | Financing Status | Location | Since |
|---|---|---|---|---|---|
| Amber Therapeutics | Biotechnology | Privately Held (backing) | Venture Capital-Backed | London, United Kingdom | |
| Arion Cancer Hospital | Hospitals/Inpatient Services | Privately Held (backing) | Private Equity-Backed | Beijing, China |
Kevin Chu Lead Partner on Deals (6)
Kevin Chu has been the lead partner on 6 deals. Their latest deal was with Amber Therapeutics, a biotechnology company. The deal was made for on 09-Jun-2024.
| Company | Deal Date | Deal Type | Deal Size | Deal Status | Industry | Location |
|---|---|---|---|---|---|---|
| Amber Therapeutics | 09-Jun-2024 | Later Stage VC (Series A) | Completed | Biotechnology | London, United Kingdom | |
| Cadence Neuroscience | 28-Feb-2023 | Completed | Therapeutic Devices | Redmond, WA | ||
| Avivomed | 16-Nov-2021 | Completed | Drug Discovery | Roseville, MN | ||
| Arion Cancer Hospital | 01-Jan-2019 | Completed | Hospitals/Inpatient Services | Beijing, China | ||
| TreeENT | 06-Jul-2018 | Early Stage VC (Series A) | Completed | Clinics/Outpatient Services | Hangzhou, China | |
| Orient Speech Therapy | 01-Jan-2015 | Later Stage VC (Series A) | Completed | Educational and Training Services (B2C) | Shenzhen, China |
Kevin Chu Network (43)
Board Members (4)
| Name | Company | Representing | Location | From |
|---|---|---|---|---|
| Liliane Chamas Ph.D | Amber Therapeutics | Oxford Science Enterprises | London, United Kingdom | |
| Aidan Crawley | Amber Therapeutics | Amber Therapeutics | London, United Kingdom | |
| Amber Therapeutics | New Enterprise Associates | London, United Kingdom | ||
| Amber Therapeutics | Lightstone Ventures | London, United Kingdom |
Portfolio Executives (18)
| Name | Company | Role | Deal date | Location |
|---|---|---|---|---|
| Tim Denison Ph.D | Amber Therapeutics | Co-Founder, Chief Technology Officer, Chief Engineer & Board Member | 09-Jun-2024 | London, United Kingdom |
| Aidan Crawley | Amber Therapeutics | Co-Founder, Chief Executive Officer & Board Member | 09-Jun-2024 | London, United Kingdom |
| Amber Therapeutics | Co-Founder & Chief Medical Officer | 09-Jun-2024 | London, United Kingdom | |
| Amber Therapeutics | Co-Founder & Chief Scientist | 09-Jun-2024 | London, United Kingdom | |
| Cadence Neuroscience | Co-Founder, President, Chief Executive Officer & Board Member | 28-Feb-2023 | Redmond, WA |
Fund Team Members (21)
| Name | Investor | Fund | Fund Location |
|---|---|---|---|
| Fang Yu | F-Prime Capital | F-Prime Capital Partners Healthcare Fund IV | Cambridge, MA |
| Carl Byers | F-Prime Capital | F-Prime Capital Partners Life Sciences Fund VI | Cambridge, MA |
| F-Prime Capital | Cambridge, MA | ||
| F-Prime Capital | Cambridge, MA | ||
| F-Prime Capital | Cambridge, MA |
Kevin Chu Affiliated Funds (4)
| Fund | Investor | Fund Type | Status | Vintage | Size | Dry Powder | IRR | IRR Quartile |
|---|---|---|---|---|---|---|---|---|
| F-Prime Capital Partners Life Sciences Fund VI | F-Prime Capital | Venture Capital - Early Stage | Closed | 2018 | ||||
| F-Prime Capital Partners Health IT and Services Fund | F-Prime Capital | Venture - General | Closed | 2018 | ||||
| F-Prime Capital Partners Healthcare Fund IV | F-Prime Capital | Venture - General | Closed | 2014 | ||||
| F-Prime Capital Partners Healthcare Fund V | F-Prime Capital | Venture - General | Closed | 2016 |
Kevin Chu FAQs
-
Who is Kevin Chu?
Mr. Kevin Chu serves as Principal at F-Prime Capital.
-
How much does Kevin Chu typically invest?
Kevin Chu's median deal size is .
-
What is Kevin Chu’s main position?
Kevin Chu’s primary position is Principal.
-
What are the contact details for Kevin Chu?
Kevin Chu’s email address is kc and his phone number is +1 (412) .
-
How many active board seats does Kevin Chu hold?
Kevin Chu holds 2 board seats including Amber Therapeutics and Arion Cancer Hospital.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
